CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation.

Palbociclib suppresses IgE-mediated mast cell activation in vitro and in vivo, suggesting that it may be developed into a therapy for mast cell-mediated allergic diseases via inhibition of mast cell degranulation.